Cardiovascular
-
Amgen Stock Faces Pressure After Rival’s Clinical Trial Miss
Amgen shares dipped following negative results from a Novartis trial, raising questions about the viability of shared cardiovascular treatment hypotheses.
Amgen shares dipped following negative results from a Novartis trial, raising questions about the viability of shared cardiovascular treatment hypotheses.